Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Tabula Rasa HealthCare, Inc. (TRHC)
|
Add to portfolio |
|
|
|
| Price: |
$44.01
| | Metrics |
| OS: |
27.1
|
M
| |
|
|
| Market cap: |
$1.19
|
B
| |
-99
|
% ROIC
|
|
Net cash:
|
$62.8
|
M
| |
$2.32
|
per share
|
|
EV:
|
$1.13
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($26.9)
|
M
| |
|
|
|
EBIT
|
($51.3)
|
M
| |
|
|
| EPS |
($2.48)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 299.5 | 259.9 | 221.4 | 284.7 | 204.3 | 133.5 | 94.8 | 70.0 |
| Revenue growth | 15.3% | 17.4% | -22.2% | 39.4% | 53.0% | 40.8% | 35.3% | 44.6% |
| Cost of goods sold | 232.6 | 193.4 | 160.6 | 181.4 | 137.7 | 93.7 | 65.2 | 49.1 |
| Gross profit | 66.9 | 66.5 | 60.8 | 103.4 | 66.6 | 39.8 | 29.6 | 20.9 |
| Gross margin | 22.3% | 25.6% | 27.4% | 36.3% | 32.6% | 29.8% | 31.2% | 29.9% |
| Sales and marketing | 10.5 | 11.0 | 8.1 | 25.3 | 9.7 | 5.5 | 3.9 | 2.9 |
| Research and development | 14.5 | 14.6 | 14.4 | 21.7 | 12.2 | 5.6 | 3.8 | 2.9 |
| General and administrative | 75.0 | 63.1 | 55.1 | 50.9 | 28.2 | 21.2 | 11.9 | 7.1 |
| EBITA | -53.0 | -35.2 | -27.0 | -7.0 | -38.6 | 9.8 | 8.0 | 8.5 |
| EBITA margin | -17.7% | -13.5% | -12.2% | -2.4% | -18.9% | 7.3% | 8.5% | 12.1% |
| Amortization of intangibles | 7.0 | 7.6 | 6.5 | 25.7 | 11.2 | 5.6 | 2.7 | 2.3 |
| EBIT | -60.0 | -42.7 | -33.5 | -32.6 | -49.7 | 4.1 | 5.3 | 6.2 |
| EBIT margin | -20.0% | -16.4% | -15.1% | -11.5% | -24.3% | 3.1% | 5.6% | 8.8% |
| Pre-tax income | -76.9 | -51.8 | -61.9 | -48.6 | -50.6 | 3.5 | -5.0 | -2.5 |
| Income taxes | 0.4 | 0.4 | -5.4 | -16.2 | -3.4 | -9.3 | 0.5 | 0.3 |
| Tax rate | | | 8.7% | 33.3% | 6.7% | | | |
| Earnings from continuing ops | -77.3 | -52.2 | -56.5 | -32.4 | -47.3 | 12.8 | -6.2 | -12.8 |
| Earnings from discontinued ops | -70.2 | -26.8 | -24.5 | | | | | |
| Net income | -147.5 | -79.1 | -81.0 | -32.4 | -47.3 | 12.8 | -6.2 | -12.8 |
| Net margin | -49.2% | -30.4% | -36.6% | -11.4% | -23.1% | 9.6% | -6.5% | -18.3% |
| |
| Diluted EPS | ($3.18) | ($2.24) | ($2.59) | ($1.57) | ($2.48) | $0.68 | ($0.53) | ($2.97) |
| Shares outstanding (diluted) | 24.3 | 23.3 | 21.8 | 20.6 | 19.1 | 18.8 | 11.6 | 4.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|